PTC Therapeutics Raises 2026 Outlook with Strong Q1 Earnings

PTC Therapeutics has raised their 2026 outlook after a strong first quarter earnings report. The increase in guidance is largely due to one of their drugs generating $125M in revenue in Q1 and shares gapped up following the earnings release.

The earnings report was widely considered a positive development for the company, driving up their shares in the market. This marks a significant milestone for PTC Therapeutics, as they continue to push forward in the healthcare sector.

While the exact nature of the company's guidance hike was not explicitly stated in the available documents, the increase in their 2026 outlook suggests a positive market outlook for the company and its stock. Analysts at Wells Fargo have set a new price target for the company, valuing it at $95.00 as of May 8th.

Related Stocks

• PTC